RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Avenue Therapeutics Stock

Avenue Therapeutics ROCE 2024

Avenue Therapeutics ROCE

-9.19

Ticker

ATXI

ISIN

US05360L2051

WKN

A2JH92

In 2024, Avenue Therapeutics's return on capital employed (ROCE) was -9.19, a 346.23% increase from the -2.06 ROCE in the previous year.

Avenue Therapeutics Aktienanalyse

What does Avenue Therapeutics do?

Avenue Therapeutics Inc is a biotechnology company specializing in the development of pain relief and anesthesia medications. The company was founded in 2015 and has since brought several products to the market. The core business of Avenue Therapeutics is the development of medications for pain and chronic pain. The company works with various compounds that selectively block pain receptors in the brain, including opioid receptors and cannabinoid receptors. The company currently has several products in the pipeline in different stages of clinical development. These include AV001, an anesthetic based on fentanyl used for pain relief in traumatic injuries and surgeries, and AV002, a pain medication based on tramadol used for acute and chronic pain. Another product being developed by the company is AV003, a synthetic cannabinoid compound that can be used for pain relief, as well as the treatment of anxiety disorders and seizures. In addition to their therapeutic effectiveness, all Avenue Therapeutics products are designed to be less addictive than traditional opioid medications. This goal is achieved through targeted dosing and special formulations. The business model of Avenue Therapeutics is based on the research, development, and marketing of pain medications and anesthetics. This includes production, clinical development, regulatory approval, and marketing in the healthcare market. Avenue Therapeutics has a wide range of customers, including hospitals, medical practices, and healthcare facilities, as well as patients suffering from pain and chronic pain. The products are offered in the North American market and can be purchased directly from the manufacturer or through sales by external distributors and retailers. An important goal of the company is to expand its product portfolio through the development of new and innovative pain medications. Therefore, the company continuously invests in research and development and collaboration with other companies and institutions to discover new technologies and compounds. However, the market for pain medications and anesthetics is highly competitive, and Avenue Therapeutics faces a range of challenges. These include stringent regulatory requirements, high costs for clinical trials, and a constant challenge to discover new technologies and compounds. Despite these challenges, Avenue Therapeutics has achieved impressive growth and a strong position in the market for pain medications and anesthetics in recent years. The company is in a good position to continue developing innovative medications in the future and provide its customers with a wide portfolio of high-quality pain relief drugs. Please indicate if these answers are enough or if you need further clarification. Avenue Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Avenue Therapeutics's Return on Capital Employed (ROCE)

Avenue Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Avenue Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Avenue Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Avenue Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Avenue Therapeutics stock

What is the ROCE (Return on Capital Employed) of Avenue Therapeutics this year?

The ROCE of Avenue Therapeutics is -9.19 undefined this year.

How has the ROCE (Return on Capital Employed) of Avenue Therapeutics developed compared to the previous year?

The ROCE of Avenue Therapeutics has increased by 346.23% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Avenue Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Avenue Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Avenue Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Avenue Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Avenue Therapeutics impact the company?

An increase in the ROCE of Avenue Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Avenue Therapeutics affect the company?

A decrease in ROCE of Avenue Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Avenue Therapeutics?

Some factors that can affect Avenue Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Avenue Therapeutics so important for investors?

The ROCE of Avenue Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Avenue Therapeutics take to improve the ROCE?

To improve the ROCE, Avenue Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Avenue Therapeutics pay?

Over the past 12 months, Avenue Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avenue Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Avenue Therapeutics?

The current dividend yield of Avenue Therapeutics is .

When does Avenue Therapeutics pay dividends?

Avenue Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avenue Therapeutics?

Avenue Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Avenue Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avenue Therapeutics located?

Avenue Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avenue Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avenue Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Avenue Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Avenue Therapeutics in the year 2023?

In the year 2023, Avenue Therapeutics distributed 0 USD as dividends.

In which currency does Avenue Therapeutics pay out the dividend?

The dividends of Avenue Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Avenue Therapeutics

Our stock analysis for Avenue Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avenue Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.